More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

S&P DJI Announces March 2021 Quarterly Rebalance

Mar 12, 2021 at 6:23 AM EST · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Mar 12, 2021 at 6:23 AM EST · 9 pages · English

On 6ix: 6ix.com/news/sandp-dji-announces-march-2021-quarterly-rebalance-69

Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20↗

Telix Pharmaceuticals Limited on 6ix

Story so far

  • S&P DJI Announces June 2020 Quarterly RebalanceJun 12, 2020

Earlier from Telix Pharmaceuticals

  • Appendix 4E - Results for announcement to the marketFeb 25, 2021
  • Shareholder update - year ended 31 December 2020Feb 25, 2021
  • Czech Republic Grants National Authorisation for TLX591 KitFeb 15, 2021
  • Appendix 4C and Activities Report for December 2020 QuarterJan 28, 2021
  • New Drug Submission filed with Health Canada for TLX591-CDxDec 15, 2020

Later from Telix Pharmaceuticals

  • TGA commences priority evaluation process for IlluccixApr 13, 2021
  • Launch of International NOBLE Registry for SPECT ImagingApr 18, 2021
  • Japanese Renal Cancer Imaging Trial Meets Study ObjectivesApr 20, 2021
  • Activities Report and App 4C for quarter ended 31 March 2021Apr 21, 2021
  • Phase III Prostate Cancer Therapy Clinical Trial CommencesMay 9, 2021
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer